Drug
BGM0504 clinical trials
Also written BGM0504.
Keep track of what changes. Save the BGM0504 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (7)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
BrightGene Bio-Medical Technology Co., Ltd. (13) · BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (1) · Second Affiliated Hospital of Soochow University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses BGM0504 is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesRecruitingPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT07658560Written as BGM0504 tablets
- A Study of BGM0504 in Early T2DM With ObesityRecruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07743983Written as BGM0504
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07166081Written as BGM0504
- Bioequivalence Study of BGM0504 InjectionCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07382908Written as BGM0504 Injection multi-dose pen
- A Study of BGM0504 Injection in Participants With Obesity or OverweightCompletedPhase 3BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.NCT06704581Written as 5 mg BGM0504 injection
- A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaActive, not recruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07064486Written as BGM0504
- A Study of BGM0504 in Participants With ObesityCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06911203Written as BGM0504
- A Study of BGM0504 in Overweight or Obese ParticipantsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06920056Written as BGM0504
- A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06929156Written as BGM0504
- A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06973681Written as BGM0504
- A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07239973Written as BGM0504 tablets
- A Study of BGM0504 Tablets in Healthy Chinese SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07566572Written as BGM0504 tablets
- A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.CompletedPhase 2Second Affiliated Hospital of Soochow UniversityNCT07836140Written as BGM0504 Administered SC
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06714955Written as Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- A Study of BGM0504 in Chinese Patients With Type 2 DiabetesCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06974825Written as BGM0504 Administered SC